AMERICAN SOCIETY of
GENE & CELL
THERAPY

Identification of Epigenetic Regulators
of *DUX4-fl* for Targeted Therapy
# of Facioscapulohumeral Muscular Dystrophy

Charis L. Himeda,[1,2] Takako I. Jones,[1,2] Ching-Man Virbasius,[3,4] Lihua Julie Zhu,[4,5] Michael R. Green,[3,4]
and Peter L. Jones[1,2]

[1]Department of Pharmacology, University of Nevada, Reno, School of Medicine, Reno, NV 89557, USA; [2]Department of Cell and Developmental Biology, University of
Massachusetts Medical School, Worcester, MA 01605, USA; [3]Howard Hughes Medical Institute, University of Massachusetts Medical School, Worcester, MA 01605,
USA; [4]Department of Molecular, Cell and Cancer Biology, University of Massachusetts Medical School, Worcester, MA 01605, USA; [5]Programs in Molecular Medicine
and Bioinformatics and Integrative Biology, University of Massachusetts Medical School, Worcester, MA 01605, USA

**Facioscapulohumeral muscular dystrophy (FSHD) is caused by
epigenetic de-repression of the disease locus, leading to patho-
genic misexpression of the DUX4 gene in skeletal muscle.
While the factors and pathways involved in normal repression
of the FSHD locus in healthy cells have been well characterized,
very little is known about those responsible for the aberrant
activation of *DUX4-fl* in FSHD myocytes. Reasoning that
DUX4-fl activators might represent useful targets for small
molecule inhibition, we performed a highly targeted, candi-
date-based screen of epigenetic regulators in primary FSHD
myocytes. We confirmed several of the strongest and most spe-
cific candidates (*ASH1L*, *BRD2*, *KDM4C*, and *SMARCA5*) in
skeletal myocytes from two other unrelated FSHD1 patients,
and we showed that knockdown led to reduced levels of
DUX4-fl and DUX4-FL target genes, as well as altered chro-
matin at the D4Z4 locus. As a second mode of validation, tar-
geting the CRISPR/dCas9-KRAB transcriptional repressor to
the promoters of several candidates also led to reduced levels
of *DUX4-fl*. Furthermore, these candidates can be repressed
by different methods in skeletal myocytes without major effects
on certain critical muscle genes. Our results demonstrate that
expression of *DUX4-fl* is regulated by multiple epigenetic path-
ways, and they indicate viable, druggable candidates for thera-
peutic target development.**

INTRODUCTION

Facioscapulohumeral muscular dystrophy (FSHD) is the third most
common muscular dystrophy,[1,2] characterized by progressive weak-
ness and atrophy of specific muscle groups. FSHD is also marked
by a high variability in disease onset, progression, and severity, which
ranges from asymptomatic to clinically severe.[1,3–5] This high vari-
ability within the clinical spectrum suggests the involvement of mul-
tiple factors, including epigenetic regulators. Indeed, both forms of
the disease are linked by epigenetic dysregulation of the D4Z4 macro-
satellite repeat array at chromosome 4q35. FSHD1, the most common
form of the disease, is linked to contractions at this array,[6–8] resulting
in relaxation of chromatin that is normally repressed. FSHD2 is

contraction independent, but mutations in proteins that maintain
epigenetic silencing lead to a similar relaxation of chromatin in the
region.[9,10] One critical consequence of this epigenetic alteration is
the aberrant expression of the *DUX4* retrogene in skeletal muscle.
While *DUX4* resides in every D4Z4 repeat unit in the macrosatellite
array, only the full-length *DUX4* mRNA (*DUX4-fl*) encoded by the
distal-most repeat is stably expressed, due to the presence of a poly-
adenylation signal in disease-permissive alleles.[11,12] The DUX4-FL
protein acts as a transcription factor and is highly cytotoxic when
overexpressed. Endogenous DUX4-FL activates germline genes,
immune mediators, and retroelements,[13,14] alters RNA and protein
metabolism,[15,16] and leads to accumulated muscle pathology.

As with many repetitive elements in the human genome, the D4Z4
macrosatellite array that encodes *DUX4* is normally under strong
epigenetic repression in adult somatic cells (reviewed in Himeda
et al.[17]). FSHD patients exhibit a loss of this repression, displaying
chromatin relaxation (reduced enrichment of the repressive
H3K9me3 mark, HP1γ, and cohesin) at D4Z4 arrays[18,19] and DNA
hypomethylation at the 4q D4Z4 array.[20–25] Thus, targeting the epige-
netic dysregulation in FSHD is a viable potential therapeutic
avenue.[17] In support of this approach, a forward genetic screen to
identify regulators of repeat-induced variegation of expression in
transgenic mice carrying a metastable repeat epiallele identified
numerous chromatin-modifying factors, classified as the *Momme*
(Modifier of Murine Metastable Epiallele) genes, involved in either re-
pressing or enhancing the variegated gene expression phenotype.[26–28]

Importantly, mice carrying mutations in genes encoding enhancers of gene expression from large DNA repeat arrays were otherwise healthy, suggesting that the levels of certain factors functioning in the regulation of large repeat arrays can be decreased without global epigenetic dysregulation.

Correction of the epigenetic defect in FSHD has been attempted in proof-of-principle studies by our lab and others, using the dCas9-KRAB transcriptional inhibitor[29] and the DICER/Argonaute system.[30] Here we took a different approach, screening a pre-selected panel of epigenetic regulators, including the human orthologs of several *Momme* genes, and chromatin-modifying enzymes for their role in maintaining *DUX4-fl* mRNA expression in primary human FSHD myocytes. Since we are keenly interested in identifying targets for developing small molecule inhibitors and therapeutics for FSHD, it was vital that our selected targets have a high potential for selective druggability. Using a combination of techniques for validation, we have uncovered several epigenetic regulators as promising targets for FSHD therapeutic development.

RESULTS

Multiple Epigenetic Pathways Regulate the Expression of *DUX4-fl* in FSHD Myocytes

Utilizing our understanding of the epigenetics impacting the FSHD region and the *Momme* enhancer genes,[17] we hypothesized that multiple epigenetic and chromatin-regulatory pathways might be deregulated in FSHD myocytes, with many potential targets for therapeutic manipulation. Since the pathogenic expression of *DUX4-fl* is restricted to differentiated human skeletal muscle, where it is expressed sporadically at very low levels, regulators of *DUX4-fl* expression are not readily amenable to high-throughput screening. Thus, we designed a highly focused, candidate-based screen in a larger format using primary FSHD myocytes. We pre-selected 36 candidate activators of *DUX4-fl* as potential drug targets based on likelihood of functioning at the contracted D4Z4 macrosatellite, activity predicting a role in transcriptional activation, or establishing or maintaining a euchromatic environment, and the presence of druggable protein domains (Table 1). Although very little is known about mechanisms of activation at D4Z4, mechanisms of repression have been well characterized. Thus, we reasoned that epigenetic regulators opposing D4Z4-repressive factors and histone marks would be good candidates for our small-scale, biased screen. These candidates include transcriptional regulators, chromatin remodelers, and histone-modifying enzymes.

For our initial screen, we used primary skeletal myocytes from an FSHD1 patient (05Abic) that express consistent and relatively high levels of *DUX4-fl* when terminally differentiated.[31] Using lentivirus-encoded small hairpin RNAs (shRNAs), we knocked down each candidate in terminally differentiated cultures, then harvested the cells 4 days later, and assessed the expression of *DUX4-fl* and other genes, including key muscle factors. The lack of a major effect on muscle genes is critically important from the perspective of ultimately developing and administering a chronic therapeutic agent. However, this also represents a potential problem with gene knockdown strate-

gies targeting ubiquitous transcriptional activators or with non-specific epigenetic drugs. Somatic *DUX4-fl* expression is predominantly restricted to differentiated skeletal muscle, due to regulation by two myogenic enhancers that activate *DUX4-fl* in an epigenetically permissive environment.[32] Therefore, any manipulation that indirectly decreases *DUX4-fl* expression by affecting myogenic differentiation or the levels of key muscle factors is not a viable therapeutic avenue for FSHD. Thus, the minimal key criteria for viable therapeutic targets emerging from our screen are those regulators whose knockdown results in a reduction of *DUX4-fl* levels without affecting the expression of critical muscle genes.

Interestingly, the results of our targeted knockdown screen revealed that many of these candidates do, in fact, appear to play a role in regulating *DUX4-fl* expression as predicted (Table S1). For example, ASH1L, the mammalian homolog of the *Drosophila* Trithorax group protein that counteracts Polycomb-mediated gene silencing, is a histone methyltransferase that has been reported to activate *DUX4-fl* expression in FSHD.[33–36] ASH1L is thought to be recruited proximal to the D4Z4 array by the *DBE-T* long noncoding RNA (lncRNA), resulting in H3K36me2 enrichment and de-repression of the FSHD locus.[36] Strikingly, we found that knockdown of *ASH1L* with three different shRNAs reduced *DUX4-fl* expression by ∼70%–80% (Figure 1A). Likewise, knockdown of the epigenetic reader *BRD2*, the lysine-specific histone demethylase *KDM4C*, and the chromatin-remodeling factors *BAZ1A* and *SMARCA5* substantially reduced levels of *DUX4-fl* (Figures 1B–1E). Importantly, these knockdowns had minimal effects on expression of the key muscle transcription factors *MYOD1* and *MYOG* (Figure 1), indicating that *DUX4-fl* repression was not caused by reduced levels of myogenic regulatory factors.[32] Levels of the muscle structural protein *MYH1* and *FRG1*, an FSHD candidate gene that lies proximal to the D4Z4 array, were also relatively unchanged (Figure 1). Depletion of *BRD2* in HeLa cells has been reported to cause widespread changes in gene expression, including a decrease in *UTRN* levels;[37] we observed a similar slight decrease in expression of *UTRN* following *BRD2* knockdown in FSHD myocytes (Figure 1C). We also confirmed that the knockdown of our top candidates does not affect the ability of myoblasts to fuse and form multinucleated myotubes (Figure S1). Thus, although a global analysis of changes in gene expression is beyond the scope of this study, these results suggest that certain epigenetic pathways controlling *DUX4-fl* expression in FSHD can be modulated without major adverse effects on muscle differentiation.

To confirm our top candidates across FSHD patient cohorts, we tested shRNA knockdowns of *ASH1L*, *BRD2*, *KDM4C*, and *SMARCA5* in myocytes from two other unrelated FSHD1 patients (18Abic and 17Abic), with similar results (Table S2). Although knockdown of these candidates was incomplete (∼40%–60% reduction in mRNA expression), at least one shRNA for each target reduced levels of *DUX4-fl* mRNA significantly in myocytes from all three patient cohorts (Figure 2; Table S3; Figure S2). As DUX4-FL protein levels are low and difficult to assess in FSHD myocytes, we chose to assess DUX4-FL target gene expression as the more reliable assay and

Table 1. Candidate Epigenetic Regulators of *DUX4-fl*

Gene	Alias	Full Name	Function
ASH1L	–	absent, small, or homeotic-like	H3K4me3, H3K36me2/3 methyltransferase
BAP1	–	BRCA1-Associated Protein 1	histone deubiquitinase; tumor suppressor
BAZ1A	ACF1	Bromodomain Adjacent to Zinc-Finger Domain 1A	ATP-dependent chromatin remodeler
BAZ1B	WSTF	Bromodomain Adjacent to Zinc-Finger Domain 1B	ATP-dependent chromatin remodeler
BAZ2A	TIP5	Bromodomain Adjacent to Zinc-Finger Domain 2A	NoRC chromatin-remodeling complex
BPTF	NURF301	Bromodomain PHD Finger Transcription Factor	NURF chromatin-remodeling complex
BRD2	–	Bromodomain containing 2	epigenetic reader
BRD3	–	Bromodomain containing 3	epigenetic reader
BRD4	–	Bromodomain containing 4	epigenetic reader
BRDT	BRD6	Bromodomain testis associated	epigenetic reader
BRPF1	–	Bromodomain and PHD Finger Containing 1	epigenetic reader; MOZ HAT complex
BRPF3	–	Bromodomain and PHD Finger Containing 3	epigenetic reader; HBO1 HAT complex
CARM1	PRMT4	Coactivator Assoc. Arginine Methyltransferase 1	H3R17 methyltransferase
KDM4A	JMJD2A	Lysine (K)-specific demethylase 4A	H3K9me3 & H3K36me3 demethylase
KDM4B	JMJD2B	Lysine (K)-specific demethylase 4B	H3K9me3 & H3K36me3 demethylase
KDM4C	JMJD2C	Lysine (K)-specific demethylase 4C	H3K9me3 & H3K36me3 demethylase
KDM4D	JMJD2D	Lysine (K)-specific demethylase 4D	H3K9me2/3 demethylase
KDM6A	UTX	Lysine (K)-specific demethylase 6A	H3K27me2/3 demethylase
KDM6B	JMJD3	Lysine (K)-specific demethylase 6B	H3K27me2/3 demethylase
KMT2A	MLL	Lysine (K)-specific methyltransferase 2A	H3K4me1/2 methyltransferase
KMT2C	MLL3	Lysine (K)-specific methyltransferase 2C	H3K4me1 methyltransferase
KMT2E	MLL5	Lysine (K)-specific methyltransferase 2E	(no methyltransferase activity)
MYSM1	–	Myb-like, SWIRM, and MPN Domains 1	histone (H2A) deubiquitinase
NEK6	–	NIMA-Related Kinase 6	histone (H1, H3) kinase
PHF2	CENP-35	PHD-Finger Protein 2	H3K9me2 demethylase
PRMT1	–	Protein Arginine Methyltransferase 1	H4R3 methyltransferase
SETD1A	KMT2F	SET Domain Containing 1A	H3K4 methyltransferase
SETD1B	KMT2G	SET Domain Containing 1B	H3K4 methyltransferase
SF3B1	SAP155	Splicing Factor 3b Subunit 1	spliceosome component; B-WICH complex
SMARCA5	SNF2H	SWI/SNF-Related, Matrix-Associated, Actin-Dependent Regulator of Chromatin, Subfamily A, Member 5	NoRC, B-WICH, NURF, ACF1, RSF, chromatin-remodeling complexes
SMARCB1	SNF5 and BAF47	SWI/SNF-Related, Matrix-Associated, Actin-Dependent Regulator of Chromatin, Subfamily B, Member 1	ATP-dependent chromatin remodeling
SMYD3	KMT3E	SET and MYND Domain Containing 3	H3K4 methyltransferase
UFL1	–	UFM1-Specific Ligase 1	E3 ligase
USP3	UBP	Ubiquitin-Specific Peptidase 3	histone (H2A, H2B, and H2AX) deubiquitinase
USP7	TEF1	Ubiquitin-Specific Peptidase 7	histone (H2A, H2B) and non-histone deubiquitinase
USP16	UBPM	Ubiquitin-Specific Peptidase 16	histone (H2A) deubiquitinase

relevant functional readout of DUX4 activity. Importantly, DUX4-FL targets thought to have pathogenic consequences[13] are significantly decreased by knockdown of all four candidates in myocytes from all three FSHD patients (Figure 2; Table S3; Figure S2). Thus, reducing individual levels of these four FSHD therapeutic targets significantly decreases expression of DUX4-fl and its downstream targets without altering the expression of certain key myogenic genes.

Transcriptional Repression of Epigenetic Regulators by dCas9-KRAB Reduces *DUX4-fl* Expression in FSHD Myocytes

In our initial screen, knockdown of eight candidates by at least two shRNAs resulted in >70% reduction of *DUX4-fl* expression, with minimal effects on other tested genes (Table S1). Based on the potential for selective druggability, we selected five of these candidates, *ASH1L*, *BAZ1A*, *BRD2*, *KDM4C*, and *SMARCA5*, for verification by

Figure 1. Knockdown of Epigenetic Regulators Reduces Expression of *DUX4-fl* in FSHD Myocytes

(A–E) Differentiated FSHD myocytes were infected in two serial rounds with lentivirus expressing shRNAs indicated in each of the panel keys specific to *ASH1L* (A), *BAZ1A* (B), *BRD2* (C), *KDM4C* (D), *SMARCA5* (E), or a scrambled control. Cells were harvested 4 days later for expression analysis of the full-length *DUX4* isoform (D4-fl), myogenin (Myog), MyoD, myosin heavy chain 1 (MyHC), *FRG1*, utrophin (Utr), and *18S* by qRT-PCR. In all panels, data are plotted as the mean + SD value of three technical replicates, with relative mRNA expression for mock-infected cells set to 1. Refer to Table S1 for results of the full screen.

an independent method. Guided by appropriate single-guide RNA(s) (sgRNA[s]), the enzymatically inactive dCas9 fused to transcriptional effectors (KRAB, LSD1, VP64, and p300) can modulate endogenous target gene expression in mammalian cells.[38–42] When recruited to regions near the transcription start site (TSS) of active genes (−50 to +250), dCas9-KRAB can be an effective transcriptional repressor,[43] and we have used it successfully to repress *DUX4-fl* expression in differentiated FSHD myocytes, which are not readily amenable to Cas9 cutting and selection.[29] Thus, for each candidate, we designed 6–8 sgRNAs targeting the promoter or exon 1, and we transduced these with dCas9-KRAB into 17Abic FSHD myocytes using four serial co-infections with centrifugation, as in our previous study.[29] Cells were harvested 72 hr later and assayed for changes in gene expression.

While none of the tested sgRNAs targeting *ASH1L* consistently affected expression of this candidate gene, we identified one functional sgRNA for *BRD2* and two independently functional sgRNAs for *BAZ1A*, *KDM4C*, and *SMARCA5* (Table S4). It is difficult to achieve strong repression of many transcriptional regulators, and although the levels of CRISPR inhibition achieved with these independent sgRNAs were modest (~20%–60%), the results were similar to those reported by other labs.[39,43] However, as with the shRNA knockdowns, even a small reduction of target gene expression proved sufficient to significantly reduce levels of *DUX4-fl* (by ~40%–60%) (Figure 3; Figure S3; Table S5), which is ideal from a therapeutic perspective. By contrast, the expression levels of other genes (*MYOD1*, *MYOG*, *MYH1*, *FRG1*, and *18S*) were

Figure 2. Knockdown of Epigenetic Regulators Reduces *DUX4-fl* and DUX4-FL Target Gene Expression across Multiple FSHD Cohorts

(A–D) Differentiated myocytes from three unrelated FSHD patients (05Abic, 17Abic, and 18Abic) were infected in two serial rounds with shRNAs to *ASH1L* (16169) (A), *BRD2* (6308) (B), *KDM4C* (22058) (C), *SMARCA5* (13214) (D), or a scrambled control. Cells were harvested 4 days later for expression analysis of shRNA target genes; *DUX4-fl*; and DUX4-FL target genes *TRIM43*, *ZSCAN4*, and *MBD3L2* by qRT-PCR. In all panels, data are plotted as the mean + SD value of three independent experiments, with relative mRNA expression for control-infected cells set to 1. *p < 0.05, **p < 0.01, and ***p < 0.001 are from comparing knockout to the corresponding control (n = 3 patients). Refer to the Materials and Methods, Figure S2, and Tables S2 and S3 for additional details.

relatively unaffected by reduction of the candidate regulator (Figure 3; Figure S3). Importantly, *DUX4-fl* was the only tested gene to be significantly reduced by both methods of repression (shRNA knockdown and CRISPR inhibition). For example, knockdown of *SMARCA5* with one shRNA (13214) resulted in a 30% decrease in *MYOD1* (Figure 1E), but this was not recapitulated by the other shRNA (13213) or by either sgRNA in the CRISPR inhibition experiment, and, thus, it likely represents an off-target effect.

Knockdown of Epigenetic Regulators Increases Chromatin Repression at the D4Z4 Macrosatellite Array

Since knocking down any of several epigenetic regulators in FSHD myocytes led to a substantial decrease in expression of *DUX4-fl*, we wanted to assess changes in chromatin at the pathogenic locus. Although *DUX4* is present in every D4Z4 repeat unit at both 4q and 10q alleles, the chromatin at three of these alleles is already in a compacted, heterochromatic state. Thus, any attempt to assess repression at the contracted allele would be dampened by the presence of the other three alleles. To remove 10q alleles from the analysis, we took advantage of a chromosome 4- versus 10-specific sequence polymorphism in the *DUX4* exon 2 in our primer design.

To assess detectable chromatin changes, we performed chromatin immunoprecipitation (ChIP) for several histone modifications following shRNA knockdown of *ASH1L*, *BRD2*, *KDM4C*, or *SMARCA5* in 17Abic FSHD myocytes. For these experiments, we used shRNAs that gave strong, consistent knockdowns of each target gene across all FSHD cohorts tested. We found that levels of the repressive H3K9me3 mark were increased in *BRD2* and *KDM4C* knockdown cells at the chromosome 4 *DUX4* exon1/intron1 (Figure 4; Figure S4). Knockdown of the H3K36 methyltransferase *ASH1L* led to the expected decrease in levels of H3K36me3 at *DUX4*; conversely, knockdown of the H3K9/H3K36 demethylase *KDM4C* led to the expected increase in both marks at *DUX4* (Figure 4; Figure S4). Although changes in enrichment were slight (~45%–85%), these differences were significant (Table S6) and likely to be an underestimate, as they reflect an increase in repression at the distal de-repressed pathogenic repeat among a background of heterochromatic 4q repeats. With regard to this, patient 17A has ~5 repeat units on the contracted 4A161 allele and ~26 repeat units on the non-contracted 4A-L161 allele. In all cases, there was no significant change in levels of enrichment at the heterochromatic 4p macrosatellite array, indicating that these epigenetic modifiers are not acting broadly at repeat regions across the genome.

Figure 3. Transcriptional Repression of Epigenetic Regulators by dCas9-KRAB Reduces Expression of *DUX4-fl* in FSHD Myocytes

(A–D) Differentiated FSHD myocytes were subjected to four serial co-infections with combinations of lentiviral supernatants expressing either dCas9-KRAB or individual sgRNAs (g1–2 for each target gene) targeting *BAZ1A* (A), *BRD2* (B), *KDM4C* (C), or *SMARCA5* (D). Cells were harvested ∼72 hr later for analysis of gene expression by qRT-PCR (as in Figure 1). Data are plotted as the mean + SD value of three independent experiments, with relative mRNA expression for cells infected with dCas9-KRAB alone set to 1. *p < 0.05 and **p < 0.01 are from comparing sgRNAs to dCas9-KRAB alone. Refer to the Materials and Methods, Figure S3, and Tables S4 and S5 for additional details.

As repressive histone modifications can lead to more stable repression in the form of DNA methylation, we performed bisulfite sequencing across the gene body of the distal pathogenic *DUX4* repeat[23] following shRNA knockdown of *ASH1L*, *BRD2*, *KDM4C*, or *SMARCA5* in 17Abic FSHD myocytes. While there were no changes in the pattern of DNA hypomethylation seen across the main gene body of *DUX4* (Figure S5A), we found that, by 4 days post-infection, there was a small increase in DNA methylation at exon 3 in *ASH1L*, *BRD2*, and *SMARCA5* knockdown cells (Figure S5B). Although the functional significance of methylation at exon 3 is unclear, knockdown of these epigenetic regulators serves to drive the methylation pattern at this region toward the higher levels seen in healthy myocytes (Figure S5B). Since primary, terminally differentiated myocytes in culture are not the ideal system in which to assess long-term changes, we expect that any substantial increase in DNA methylation will require assessment in a more physiologically relevant model.

In summary, using several different methods, we have demonstrated that independent knockdown of multiple chromatin regulators results in chromatin repression at D4Z4 and a substantial decrease in *DUX4-fl* expression in FSHD myocytes. Our results provide proof of principle that even modest inhibition of certain epigenetic pathways can substantially reduce levels of *DUX4-fl*, demonstrating their potential as novel drug targets for FSHD.

DISCUSSION

In a previous study, we successfully corrected the underlying defect in FSHD by using dCas9-KRAB (CRISPR inhibition) to return the aberrantly relaxed chromatin at the disease locus to a more repressed state.[29] However, due to limitations in current technology and delivery, our CRISPR inhibition approach is many years away from being clinically applicable. Small molecule therapeutics targeting the regulatory factors modulating *DUX4-fl* expression at the FSHD locus could overcome these limitations. Therefore, here we took a different approach to this correction, identifying the potentially druggable chromatin-regulatory pathways converging on the contracted FSHD1 D4Z4 macrosatellite repeat, which represent therapeutic targets for designing inhibitory molecules. Using two complementary modalities to knock down specific candidate regulators, we found that many of these pathways serve to regulate *DUX4-fl* expression in FSHD myocytes. Importantly, while we have focused on only several of these factors, the results from our initial screen indicate that there are many viable potential candidates for FSHD drug development, for any investigator who wishes to pursue them.

The identification of multiple candidate regulators of *DUX4-fl* is perhaps not surprising, as many of these factors are part of the same multi-protein complexes or function in the same regulatory pathways (Table 2). For instance, SMARCA5 is a catalytic component

Figure 4. Knockdown of Epigenetic Regulators Alters Chromatin at the D4Z4 Macrosatellite Array

(A and B) Differentiated FSHD myocytes were infected in two serial rounds with shRNAs to *ASH1L*, *BRD2*, *KDM4C*, *SMARCA5*, an empty control, or a GFP control. Cells were harvested 4 days later for ChIP analysis. Chromatin was immunoprecipitated using antibodies specific for H3K9me3 (A), H3K36me3 (B), or H3, and it was analyzed by qPCR using primers specific to *DUX4* exon1/intron1 on chromosome 4 (4q-spec DUX4) or the 4p macrosatellite array on chromosome 4. Data are presented as fold enrichment of the target region by αH3K9me3 or αH3K36me3 normalized to α-histone H3, with enrichment for the empty control shRNA-infected cells set to 1. Data are plotted as the mean + SD value of at least three independent experiments. *$p < 0.05$, **$p < 0.01$, and ***$p < 0.001$ are from comparing knockout to the corresponding empty control. Refer to the Materials and Methods, Figure S4, and Table S6 for additional details.

of at least five chromatin-remodeling complexes (CHRAC, RSF, ACF/WCRF, B-WICH, and NoRC[44–48]). SMARCA5 directly associates with BAZ1A and BAZ2A, two other candidates from our screen, in two distinct chromatin-remodeling complexes that enable DNA replication through repressive chromatin and mediate heterochromatin formation at repetitive elements, respectively.[49,50] SMARCA5 is also part of the B-WICH-remodeling complex—which includes two other candidates from our screen, BAZ1B and the splicing factor SF3B1—and part of the NURF complex with BPTF[51] (Table 2). These complex interaction networks, and the large families these factors belong to, are largely responsible for the toxicity of current epigenetic drugs. However, as with the *Momme* genetic screen,[26] our results demonstrate that the reduction of certain epigenetic regulators can have relatively specific effects. While a global gene expression analysis would likely find other changes, it is clear that our candidates are not global regulators and have some specificity for D4Z4 arrays. This specificity is not without precedent, as many repressive epigenetic factors are relatively specific for the chromosome 4q and 10q D4Z4 arrays.[17] For example, the highly specific *de novo* DNA methyltransferase DNMT3B is localized at D4Z4 arrays,[52,53] and SMCHD1, the chromatin-remodeling protein responsible for FSHD2, has a very restricted genomic distribution, including D4Z4 macrosatellites.[10,54]

The identification of potential targets from screens such as ours should facilitate the development of more specific small molecule inhibitors. For example, consistent with our results, a recent report indicates that BET bromodomain inhibition decreases *DUX4* expression in FSHD myocytes.[55] However, the results of our epigenetic screen indicate that pan-BRD inhibition is not necessary or even desirable as a treatment for FSHD. We found that *BRD2* knockdown represses *DUX4-fl* levels without major effects on muscle genes, whereas knockdown of *BRD3* or *BRD4* either led to substantial effects on other genes or was less effective at decreasing *DUX4-fl*. Thus, the

development of drugs targeting specific isoforms as well as specific protein interactions should decrease adverse effects, leading to greater safety and efficacy. This is particularly important, since combination therapies may ultimately prove to be the most effective means of treating FSHD.

These epigenetic regulators have wide-ranging roles (e.g., cell proliferation, differentiation, DNA repair, and apoptosis); thus, it is possible that they are affecting *DUX4-fl* expression indirectly. However, they are most likely reducing *DUX4-fl* expression by modifying the chromatin state at the pathogenic locus. Even a modest reduction in expression of these factors led to enhanced chromatin repression at the chromosome 4q D4Z4 array, detectable even on a background of heterochromatic repeats, and a striking decrease in *DUX4-fl* expression. The ability to modulate levels of *DUX4-fl* without completely abolishing expression of its upstream regulators, all of which play important and diverse cellular roles, is particularly encouraging for the development of targeted therapies. Within FSHD families, asymptomatic individuals still express detectable levels of *DUX4-fl* (lower than those of their manifesting siblings),[24,31] suggesting that DUX4 expression doesn't need to be completely silenced, merely reduced, to see a therapeutic effect. The catastrophic effects of small increases in *DUX4-fl* levels in mouse models[56,57] also suggest that even small decreases in expression will be beneficial to patients. While the establishment of stable, long-term repression will be important to demonstrate, we found that knockdown of several regulators led to an increase in DNA methylation at exon 3 of *DUX4* as early as 4 days post-infection. Unfortunately, primary FSHD myotubes—which are not undergoing replication and are not amenable to gene editing, selection, or long-term culturing—are not the best model in which to test long-term epigenetic changes. Cells such as the newly reported FSHD lymphoblast lines, which express *DUX4-fl* mRNA and mimic patterns of DNA methylation seen in FSHD myocytes,[58] would be

Table 2. Top Therapeutic Candidates for Targeted Repression of *DUX4-fl*

Candidate	Target Domains	Function and Complexes	Candidate Interactions
ASH1L	SET,[63] Bromo,[64] BAH,[65] and PHD[66]	H3K36me2/3 methyltransferase	–
BAZ1A/ACF1	Bromo,[64] PHD,[66] and WAC[67]	non-catalytic component that enhances and directs function of SMARCA5 in the CHRAC- and ACF-remodeling complexes	SMARCA5
BRD2	Bromo1 and Bromo2[64]	binds hyperacetylated chromatin; regulates transcription	–
KDM4C/JMJD2C	jmjN/jmjC[68] and PHD[66]	H3K9me3 and H3K36me3 demethylase	PRMT1
SMARCA5/SNF2H	Helicase ATP-binding, Helicase C,[69] SANT1, and SANT2[70]	catalytic subunit of ATP-dependent chromatin-remodeling complexes (CHRAC, RSF, ACF, B-WICH, NoRC, and NURF)	BAZ1A, BAZ1B, BAZ2A, SF3B1, and BPTF

better suited for assessing DNA methylation changes in response to the depletion of *DUX4-fl* regulators. In response to epigenetic drugs, these lymphoblasts show a similar induction of *DUX4-fl* expression to that seen in FSHD myocytes,[58] suggesting that at least some upstream regulatory pathways are maintained in non-muscle cells.

It is likely that multiple epigenetic pathways have evolved to repress repetitive elements within the human genome. The *DUX4* retrogene appears to have a normal developmental role in the testis;[12] however, silencing of *DUX4* and the D4Z4 macrosatellite repeat is critical in somatic tissues. Although *DUX4-fl* is only rarely expressed in FSHD myocytes at any given time, it is epigenetically poised for expression in a majority of these cells,[24,29] indicating a general deregulation of repressive upstream mechanisms. Our results suggest that, in the absence of normal repression, activating pathways are aberrantly active and even modest perturbations in these pathways may be sufficient to reduce levels of *DUX4-fl*.

How these regulators activate *DUX4* in FSHD myocytes is an important question that may bear on the normal function of *DUX4* during development. *DUX4* is normally expressed in the testis, where epigenetic mechanisms are critically important for regulating spermatogenesis. The abnormal activation of testis genes is not unprecedented: cancer/testis antigens—genes normally expressed in the male germline that encode immunogenic proteins—are epigenetically activated in many types of cancer. Interestingly, many DUX4-FL targets are also cancer/testis antigens.[13] Although the mechanisms controlling *DUX4* expression in germ cells are still uncharacterized, the upstream enhancers driving *DUX4* transcription in FSHD myocytes contain elements for both muscle and testis factors.[32] Thus, it seems plausible that, in the absence of normal somatic repression, epigenetic pathways that activate *DUX4* in the testis could be aberrantly activated in skeletal muscle, allowing muscle factors inappropriate access to *DUX4*-regulatory regions. Further characterization of these mechanisms should help to uncover additional targets for therapeutic development.

MATERIALS AND METHODS

Plasmids and Antibodies

The pHAGE EF1-dCas9-KRAB (Addgene plasmid 50919) and pLKO.1-puro U6 sgRNA BfuAI stuffer lentiviral plasmids were developed by Rene Maehr and Scot Wolfe (Addgene plasmid 50920).[40] The ChIP-grade antibodies used in this study, α-H3K9me3 (ab8898), α-H3K36me3 (ab9050), and α-histone H3 (ab1791), were purchased from Abcam (Cambridge, MA).

sgRNA Design and Plasmid Construction

We used the publicly available sgRNA design tool from the Broad Institute (http://www.broadinstitute.org/rnai/public/analysis-tools/sgrna-design) to identify candidate sgRNAs targeting the promoter/exon 1 regions of human *BAZ1A*, *BRD2*, *KDM4C*, and *SMARCA5* (Supplemental Information; Table S4). To build in flexibility for experiments beyond the scope of this study, we prioritized sgRNAs that target sequences flanking dual protospacer adjacent motifs (PAMs) recognizable by both SaCas9 and SpCas9. Predicted off-target matches were determined using the CRISPR Design Tool (http://crispr.mit.edu).[59] 6–8 sgRNAs for each target gene were cloned individually into BfuAI sites in the pLKO.1-puro U6 sgRNA BfuAI stuffer plasmid and sequence verified.

Cell Culture, Transient Transfections, and Lentiviral Infections

Myogenic cells were obtained from the Wellstone FSHD cell repository housed at the University of Massachusetts Medical School,[24,31] and normal human primary myoblasts were obtained from Lonza (HSMM, lot 509793). Myogenic cultures derived from biceps muscles of unrelated FSHD1 patients (05Abic, 17Abic, and 18Abic), normal myoblasts, and 293T packaging cells were grown as described.[29] Lentiviral particles expressing shRNAs were generated using The RNAi Consortium (TRC) shRNA expression plasmids as previously described,[60] and they were obtained through the University of Massachusetts Medical School RNAi Core Facility. FSHD1 skeletal myoblasts were grown to confluence, and then allowed to self-differentiate in growth medium for ~48 hr. Cells were subjected to 2 rounds of infection and harvested 4 days later (for shRNA knockdowns and ChIP) or 4 rounds of infection and harvested 3 days later (for CRISPR inhibition experiments), as described.[29] For the assessment of fusion index, normal primary myoblasts were switched to differentiation conditions[24,31] following shRNA knockdown.

qRT-PCR

Total RNAs were extracted using TRIzol (Invitrogen) and purified using the RNeasy Mini kit (QIAGEN) after on-column DNase I

digestion. Total RNA (2 µg) was used for cDNA synthesis using Superscript III Reverse Transcriptase (Invitrogen), and 200 ng cDNA was used for qPCR analysis as described.[24] Oligonucleotide primer sequences are provided in Table S7.

ChIP

ChIP assays were performed with lentiviral-infected 17Abic differentiated myocytes using the Fast ChIP method[61] as described.[29] Chromatin was immunoprecipitated using 2 µg specific antibodies. SYBR green qPCR assays were performed as described.[29] Oligonucleotide primer sequences are provided in Table S7.

Bisulfite Sequencing

Bisulfite sequencing (BSS) was performed on genomic DNAs isolated from lentiviral-infected 17Abic differentiated myocytes. DNA methylation at the distal pathogenic D4Z4 repeat was analyzed using the 4qA BSS assay as described[23,24] or using primers amplifying exon 3 from 4qA (Table S7).

Statistics

Statistical analysis was performed using R[62] with log2-transformed gene expression or ChIP enrichment data. Levene's test shows that the assumption of homogeneity of variances is met. Pre-determined contrast was made between knockout and the corresponding empty vector within the framework of ANOVA using randomized block design (patient as block for Figure 2, experiment as block for Figures 3 and 4; n = 3–5). Fusion index (Figure S1) was first arcsine-transformed to homogenize the variance. Levene's test shows that the assumption of homogeneity of variances is met. ANOVA of the randomized block design was performed followed by predetermined contrasts.

SUPPLEMENTAL INFORMATION

Supplemental Information includes five figures and seven tables and can be found with this article online at https://doi.org/10.1016/j.ymthe.2018.04.019.

AUTHOR CONTRIBUTIONS

M.R.G. conceived of the project. C.L.H., T.I.J., M.R.G., and P.L.J. designed research. C.L.H. and T.I.J. performed research. C.-M.V. and M.R.G. contributed new reagents. C.L.H., L.J.Z., M.R.G., and P.L.J. analyzed data. C.L.H., L.J.Z., M.R.G., and P.L.J. wrote the paper.

CONFLICTS OF INTEREST

The results described in this manuscript are part of a patent application that has been licensed by Fulcrum Therapeutics. P.L.J. and M.R.G. are scientific advisors to Fulcrum Therapeutics; C.L.H. is a scientific consultant to Fulcrum Therapeutics.

ACKNOWLEDGMENTS

REFERENCES

1. Padberg, G.W. (1982). Facioscapulohumeral disease. Thesis (Leiden, the Netherlands: Leiden University).

2. Orphanet (2016). Prevalence and incidence of rare diseases: bibliographic data. http://www.orpha.net/orphacom/cahiers/docs/GB/Prevalence_of_rare_diseases_by_alphabetical_list.pdf.

3. Tawil, R., Forrester, J., Griggs, R.C., Mendell, J., Kissel, J., McDermott, M., King, W., Weiffenbach, B., and Figlewicz, D.; The FSH-DY Group (1996). Evidence for anticipation and association of deletion size with severity in facioscapulohumeral muscular dystrophy. Ann. Neurol. 39, 744–748.

4. Tonini, M.M., Passos-Bueno, M.R., Cerqueira, A., Matioli, S.R., Pavanello, R., and Zatz, M. (2004). Asymptomatic carriers and gender differences in facioscapulohumeral muscular dystrophy (FSHD). Neuromuscul. Disord. 14, 33–38.

5. Wang, L.H., and Tawil, R. (2016). Facioscapulohumeral Dystrophy. Curr. Neurol. Neurosci. Rep. 16, 66.

6. Wijmenga, C., Frants, R.R., Brouwer, O.F., Moerer, P., Weber, J.L., and Padberg, G.W. (1990). Location of facioscapulohumeral muscular dystrophy gene on chromosome 4. Lancet 336, 651–653.

7. Wijmenga, C., Hewitt, J.E., Sandkuijl, L.A., Clark, L.N., Wright, T.J., Dauwerse, H.G., Gruter, A.M., Hofker, M.H., Moerer, P., Williamson, R., et al. (1992). Chromosome 4q DNA rearrangements associated with facioscapulohumeral muscular dystrophy. Nat. Genet. 2, 26–30.

8. van Deutekom, J.C., Wijmenga, C., van Tienhoven, E.A., Gruter, A.M., Hewitt, J.E., Padberg, G.W., van Ommen, G.J., Hofker, M.H., and Frants, R.R. (1993). FSHD associated DNA rearrangements are due to deletions of integral copies of a 3.2 kb tandemly repeated unit. Hum. Mol. Genet. 2, 2037–2042.

9. van den Boogaard, M.L., Lemmers, R.J.L.F., Balog, J., Wohlgemuth, M., Auranen, M., Mitsuhashi, S., van der Vliet, P.J., Straasheijm, K.R., van den Akker, R.F.P., Kriek, M., et al. (2016). Mutations in DNMT3B Modify Epigenetic Repression of the D4Z4 Repeat and the Penetrance of Facioscapulohumeral Dystrophy. Am. J. Hum. Genet. 98, 1020–1029.

10. Lemmers, R.J., Tawil, R., Petek, L.M., Balog, J., Block, G.J., Santen, G.W., Amell, A.M., van der Vliet, P.J., Almomani, R., Straasheijm, K.R., et al. (2012). Digenic inheritance of an SMCHD1 mutation and an FSHD-permissive D4Z4 allele causes facioscapulohumeral muscular dystrophy type 2. Nat. Genet. 44, 1370–1374.

11. Lemmers, R.J., van der Vliet, P.J., Klooster, R., Sacconi, S., Camaño, P., Dauwerse, J.G., Snider, L., Straasheijm, K.R., van Ommen, G.J., Padberg, G.W., et al. (2010). A unifying genetic model for facioscapulohumeral muscular dystrophy. Science 329, 1650–1653.

12. Snider, L., Geng, L.N., Lemmers, R.J., Kyba, M., Ware, C.B., Nelson, A.M., Tawil, R., Filippova, G.N., van der Maarel, S.M., Tapscott, S.J., and Miller, D.G. (2010). Facioscapulohumeral dystrophy: incomplete suppression of a retrotransposed gene. PLoS Genet. 6, e1001181.

13. Geng, L.N., Yao, Z., Snider, L., Fong, A.P., Cech, J.N., Young, J.M., van der Maarel, S.M., Ruzzo, W.L., Gentleman, R.C., Tawil, R., and Tapscott, S.J. (2012). DUX4 activates germline genes, retroelements, and immune mediators: implications for facioscapulohumeral dystrophy. Dev. Cell 22, 38–51.

14. Young, J.M., Whiddon, J.L., Yao, Z., Kasinathan, B., Snider, L., Geng, L.N., Balog, J., Tawil, R., van der Maarel, S.M., and Tapscott, S.J. (2013). DUX4 binding to retroelements creates promoters that are active in FSHD muscle and testis. PLoS Genet. 9, e1003947.

15. Homma, S., Beermann, M.L., Boyce, F.M., and Miller, J.B. (2015). Expression of FSHD-related DUX4-FL alters proteostasis and induces TDP-43 aggregation. Ann. Clin. Transl. Neurol. 2, 151–166.

16. Feng, Q., Snider, L., Jagannathan, S., Tawil, R., van der Maarel, S.M., Tapscott, S.J., and Bradley, R.K. (2015). A feedback loop between nonsense-mediated decay and the retrogene DUX4 in facioscapulohumeral muscular dystrophy. eLife 4, e04996.

17. Himeda, C.L., Jones, T.I., and Jones, P.L. (2015). Facioscapulohumeral muscular dystrophy as a model for epigenetic regulation and disease. Antioxid. Redox Signal. 22, 1463–1482.

18. Zeng, W., de Greef, J.C., Chen, Y.Y., Chien, R., Kong, X., Gregson, H.C., Winokur, S.T., Pyle, A., Robertson, K.D., Schmiesing, J.A., et al. (2009). Specific loss of histone H3 lysine 9 trimethylation and HP1gamma/cohesin binding at D4Z4 repeats is associated with facioscapulohumeral dystrophy (FSHD). PLoS Genet. 5, e1000559.

19. Balog, J., Miller, D., Sanchez-Curtailles, E., Carbo-Marques, J., Block, G., Potman, M., de Knijff, P., Lemmers, R.J., Tapscott, S.J., and van der Maarel, S.M. (2012). Epigenetic regulation of the X-chromosomal macrosatellite repeat encoding for the cancer/testis gene CT47. Eur. J. Hum. Genet. 20, 185–191.

20. van Overveld, P.G., Lemmers, R.J., Sandkuijl, L.A., Enthoven, L., Winokur, S.T., Bakels, F., Padberg, G.W., van Ommen, G.J., Frants, R.R., and van der Maarel, S.M. (2003). Hypomethylation of D4Z4 in 4q-linked and non-4q-linked facioscapulohumeral muscular dystrophy. Nat. Genet. 35, 315–317.

21. van Overveld, P.G., Enthoven, L., Ricci, E., Rossi, M., Felicetti, L., Jeanpierre, M., Winokur, S.T., Frants, R.R., Padberg, G.W., and van der Maarel, S.M. (2005). Variable hypomethylation of D4Z4 in facioscapulohumeral muscular dystrophy. Ann. Neurol. 58, 569–576.

22. de Greef, J.C., Lemmers, R.J., van Engelen, B.G., Sacconi, S., Venance, S.L., Frants, R.R., Tawil, R., and van der Maarel, S.M. (2009). Common epigenetic changes of D4Z4 in contraction-dependent and contraction-independent FSHD. Hum. Mutat. 30, 1449–1459.

23. Jones, T.I., Yan, C., Sapp, P.C., McKenna-Yasek, D., Kang, P.B., Quinn, C., Salameh, J.S., King, O.D., and Jones, P.L. (2014). Identifying diagnostic DNA methylation profiles for facioscapulohumeral muscular dystrophy in blood and saliva using bisulfite sequencing. Clin. Epigenetics 6, 23.

24. Jones, T.I., King, O.D., Himeda, C.L., Homma, S., Chen, J.C., Beermann, M.L., Yan, C., Emerson, C.P., Jr., Miller, J.B., Wagner, K.R., and Jones, P.L. (2015). Individual epigenetic status of the pathogenic D4Z4 macrosatellite correlates with disease in facioscapulohumeral muscular dystrophy. Clin. Epigenetics 7, 37.

25. Lemmers, R.J., Goeman, J.J., van der Vliet, P.J., van Nieuwenhuizen, M.P., Balog, J., Vos-Versteeg, M., Camano, P., Ramos Arroyo, M.A., Jerico, I., Rogers, M.T., et al. (2015). Inter-individual differences in CpG methylation at D4Z4 correlate with clinical variability in FSHD1 and FSHD2. Hum. Mol. Genet. 24, 659–669.

26. Blewitt, M.E., Vickaryous, N.K., Hemley, S.J., Ashe, A., Bruxner, T.J., Preis, J.I., Arkell, R., and Whitelaw, E. (2005). An N-ethyl-N-nitrosourea screen for genes involved in variegation in the mouse. Proc. Natl. Acad. Sci. USA 102, 7629–7634.

27. Ashe, A., Morgan, D.K., Whitelaw, N.C., Bruxner, T.J., Vickaryous, N.K., Cox, L.L., Butterfield, N.C., Wicking, C., Blewitt, M.E., Wilkins, S.J., et al. (2008). A genome-wide screen for modifiers of transgene variegation identifies genes with critical roles in development. Genome Biol. 9, R182.

28. Daxinger, L., Harten, S.K., Oey, H., Epp, T., Isbel, L., Huang, E., Whitelaw, N., Apedaile, A., Sorolla, A., Yong, J., et al. (2013). An ENU mutagenesis screen identifies novel and known genes involved in epigenetic processes in the mouse. Genome Biol. 14, R96.

29. Himeda, C.L., Jones, T.I., and Jones, P.L. (2016). CRISPR/dCas9-mediated Transcriptional Inhibition Ameliorates the Epigenetic Dysregulation at D4Z4 and Represses DUX4-fl in FSH Muscular Dystrophy. Mol. Ther. 24, 527–535.

30. Lim, J.W., Snider, L., Yao, Z., Tawil, R., Van Der Maarel, S.M., Rigo, F., Bennett, C.F., Filippova, G.N., and Tapscott, S.J. (2015). DICER/AGO-dependent epigenetic silencing of D4Z4 repeats enhanced by exogenous siRNA suggests mechanisms and therapies for FSHD. Hum. Mol. Genet. 24, 4817–4828.

31. Jones, T.I., Chen, J.C., Rahimov, F., Homma, S., Arashiro, P., Beermann, M.L., King, O.D., Miller, J.B., Kunkel, L.M., Emerson, C.P., Jr., et al. (2012). Facioscapulohumeral muscular dystrophy family studies of DUX4 expression: evidence for disease modifiers and a quantitative model of pathogenesis. Hum. Mol. Genet. 21, 4419–4430.

32. Himeda, C.L., Debarnot, C., Homma, S., Beermann, M.L., Miller, J.B., Jones, P.L., and Jones, T.I. (2014). Myogenic enhancers regulate expression of the facioscapulohumeral muscular dystrophy-associated DUX4 gene. Mol. Cell. Biol. 34, 1942–1955.

33. An, S., Yeo, K.J., Jeon, Y.H., and Song, J.J. (2011). Crystal structure of the human histone methyltransferase ASH1L catalytic domain and its implications for the regulatory mechanism. J. Biol. Chem. 286, 8369–8374.

34. Miyazaki, H., Higashimoto, K., Yada, Y., Endo, T.A., Sharif, J., Komori, T., Matsuda, M., Koseki, Y., Nakayama, M., Soejima, H., et al. (2013). Ash1l methylates Lys36 of histone H3 independently of transcriptional elongation to counteract polycomb silencing. PLoS Genet. 9, e1003897.

35. Gregory, G.D., Vakoc, C.R., Rozovskaia, T., Zheng, X., Patel, S., Nakamura, T., Canaani, E., and Blobel, G.A. (2007). Mammalian ASH1L is a histone methyltransferase that occupies the transcribed region of active genes. Mol. Cell. Biol. 27, 8466–8479.

36. Cabianca, D.S., Casa, V., Bodega, B., Xynos, A., Ginelli, E., Tanaka, Y., and Gabellini, D. (2012). A long ncRNA links copy number variation to a polycomb/trithorax epigenetic switch in FSHD muscular dystrophy. Cell 149, 819–831.

37. Hnilicová, J., Hozeifi, S., Stejskalová, E., Dušková, E., Poser, I., Humpolíčková, J., Hof, M., and Staněk, D. (2013). The C-terminal domain of Brd2 is important for chromatin interaction and regulation of transcription and alternative splicing. Mol. Biol. Cell 24, 3557–3568.

38. Gilbert, L.A., Horlbeck, M.A., Adamson, B., Villalta, J.E., Chen, Y., Whitehead, E.H., Guimaraes, C., Panning, B., Ploegh, H.L., Bassik, M.C., et al. (2014). Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation. Cell 159, 647–661.

39. Gilbert, L.A., Larson, M.H., Morsut, L., Liu, Z., Brar, G.A., Torres, S.E., Stern-Ginossar, N., Brandman, O., Whitehead, E.H., Doudna, J.A., et al. (2013). CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell 154, 442–451.

40. Kearns, N.A., Genga, R.M., Enuameh, M.S., Garber, M., Wolfe, S.A., and Maehr, R. (2014). Cas9 effector-mediated regulation of transcription and differentiation in human pluripotent stem cells. Development 141, 219–223.

41. Kearns, N.A., Pham, H., Tabak, B., Genga, R.M., Silverstein, N.J., Garber, M., and Maehr, R. (2015). Functional annotation of native enhancers with a Cas9-histone demethylase fusion. Nat. Methods 12, 401–403.

42. Hilton, I.B., D'Ippolito, A.M., Vockley, C.M., Thakore, P.I., Crawford, G.E., Reddy, T.E., and Gersbach, C.A. (2015). Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers. Nat. Biotechnol. 33, 510–517.

43. Radzisheuskaya, A., Shlyueva, D., Müller, I., and Helin, K. (2016). Optimizing sgRNA position markedly improves the efficiency of CRISPR/dCas9-mediated transcriptional repression. Nucleic Acids Res. 44, e141.

44. Längst, G., and Becker, P.B. (2001). Nucleosome mobilization and positioning by ISWI-containing chromatin-remodeling factors. J. Cell Sci. 114, 2561–2568.

45. Bozhenok, L., Wade, P.A., and Varga-Weisz, P. (2002). WSTF-ISWI chromatin remodeling complex targets heterochromatic replication foci. EMBO J. 21, 2231–2241.

46. Loyola, A., Huang, J.Y., LeRoy, G., Hu, S., Wang, Y.H., Donnelly, R.J., Lane, W.S., Lee, S.C., and Reinberg, D. (2003). Functional analysis of the subunits of the chromatin assembly factor RSF. Mol. Cell. Biol. 23, 6759–6768.

47. Poot, R.A., Bozhenok, L., van den Berg, D.L., Hawkes, N., and Varga-Weisz, P.D. (2005). Chromatin remodeling by WSTF-ISWI at the replication site: opening a window of opportunity for epigenetic inheritance? Cell Cycle 4, 543–546.

48. Strohner, R., Nemeth, A., Jansa, P., Hofmann-Rohrer, U., Santoro, R., Längst, G., and Grummt, I. (2001). NoRC–a novel member of mammalian ISWI-containing chromatin remodeling machines. EMBO J. 20, 4892–4900.

49. Collins, N., Poot, R.A., Kukimoto, I., García-Jiménez, C., Dellaire, G., and Varga-Weisz, P.D. (2002). An ACF1-ISWI chromatin-remodeling complex is required for DNA replication through heterochromatin. Nat. Genet. 32, 627–632.

50. Guetg, C., Lienemann, P., Sirri, V., Grummt, I., Hernandez-Verdun, D., Hottiger, M.O., Fussenegger, M., and Santoro, R. (2010). The NoRC complex mediates the heterochromatin formation and stability of silent rRNA genes and centromeric repeats. EMBO J. 29, 2135–2146.

51. Cavellán, E., Asp, P., Percipalle, P., and Farrants, A.K. (2006). The WSTF-SNF2h chromatin remodeling complex interacts with several nuclear proteins in transcription. J. Biol. Chem. 281, 16264–16271.

52. Okano, M., Bell, D.W., Haber, D.A., and Li, E. (1999). DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 99, 247–257.

53. Hansen, R.S., Wijmenga, C., Luo, P., Stanek, A.M., Canfield, T.K., Weemaes, C.M., and Gartler, S.M. (1999). The DNMT3B DNA methyltransferase gene is mutated in the ICF immunodeficiency syndrome. Proc. Natl. Acad. Sci. USA 96, 14412–14417.

54. Mason, A.G., Slieker, R.C., Balog, J., Lemmers, R.J.L.F., Wong, C.J., Yao, Z., Lim, J.W., Filippova, G.N., Ne, E., Tawil, R., et al. (2017). SMCHD1 regulates a limited set of gene clusters on autosomal chromosomes. Skelet. Muscle 7, 12.

55. Campbell, A.E., Oliva, J., Yates, M.P., Zhong, J.W., Shadle, S.C., Snider, L., Singh, N., Tai, S., Hiramuki, Y., Tawil, R., et al. (2017). BET bromodomain inhibitors and agonists of the beta-2 adrenergic receptor identified in screens for compounds that inhibit DUX4 expression in FSHD muscle cells. Skelet. Muscle 7, 16.

56. Bosnakovski, D., Chan, S.S.K., Recht, O.O., Hartweck, L.M., Gustafson, C.J., Athman, L.L., Lowe, D.A., and Kyba, M. (2017). Muscle pathology from stochastic low level DUX4 expression in an FSHD mouse model. Nat. Commun. 8, 550.

57. Jones, T., and Jones, P.L. (2018). A cre-inducible DUX4 transgenic mouse model for investigating facioscapulohumeral muscular dystrophy. PLoS ONE 13, e0192657.

58. Jones, T.I., Himeda, C.L., Perez, D.P., and Jones, P.L. (2017). Large family cohorts of lymphoblastoid cells provide a new cellular model for investigating facioscapulohumeral muscular dystrophy. Neuromuscul. Disord. 27, 221–238.

59. Hsu, P.D., Scott, D.A., Weinstein, J.A., Ran, F.A., Konermann, S., Agarwala, V., Li, Y., Fine, E.J., Wu, X., Shalem, O., et al. (2013). DNA targeting specificity of RNA-guided Cas9 nucleases. Nat. Biotechnol. 31, 827–832.

60. Ma, L., Roderick, J., Kelliher, M.A., and Green, M.R. (2016). High-Throughput Screening of Tyrosine Kinase Inhibitor Resistant Genes in CML. Methods Mol. Biol. 1465, 159–173.

61. Nelson, J.D., Denisenko, O., and Bomsztyk, K. (2006). Protocol for the fast chromatin immunoprecipitation (ChIP) method. Nat. Protoc. 1, 179–185.

62. Ihaka, R., and Gentleman, R. (1996). R: A language for data analysis and graphics. J. Comput. Graph. Stat. 5, 299–314.

63. Jenuwein, T., Laible, G., Dorn, R., and Reuter, G. (1998). SET domain proteins modulate chromatin domains in eu- and heterochromatin. Cell. Mol. Life Sci. 54, 80–93.

64. Owen, D.J., Ornaghi, P., Yang, J.C., Lowe, N., Evans, P.R., Ballario, P., Neuhaus, D., Filetici, P., and Travers, A.A. (2000). The structural basis for the recognition of acetylated histone H4 by the bromodomain of histone acetyltransferase gcn5p. EMBO J. 19, 6141–6149.

65. Callebaut, I., Courvalin, J.C., and Mornon, J.P. (1999). The BAH (bromo-adjacent homology) domain: a link between DNA methylation, replication and transcriptional regulation. FEBS Lett. 446, 189–193.

66. Sanchez, R., and Zhou, M.M. (2011). The PHD finger: a versatile epigenome reader. Trends Biochem. Sci. 36, 364–372.

67. Fyodorov, D.V., and Kadonaga, J.T. (2002). Binding of Acf1 to DNA involves a WAC motif and is important for ACF-mediated chromatin assembly. Mol. Cell. Biol. 22, 6344–6353.

68. Mosammaparast, N., and Shi, Y. (2010). Reversal of histone methylation: biochemical and molecular mechanisms of histone demethylases. Annu. Rev. Biochem. 79, 155–179.

69. Narlikar, G.J., Sundaramoorthy, R., and Owen-Hughes, T. (2013). Mechanisms and functions of ATP-dependent chromatin-remodeling enzymes. Cell 154, 490–503.

70. Horton, J.R., Elgar, S.J., Khan, S.I., Zhang, X., Wade, P.A., and Cheng, X. (2007). Structure of the SANT domain from the Xenopus chromatin remodeling factor ISWI. Proteins 67, 1198–1202.